New approaches to studying early brain development in Down syndrome

Ana A Baburamani, Prachi A Patkee, Tomoki Arichi, Mary A Rutherford, Ana A Baburamani, Prachi A Patkee, Tomoki Arichi, Mary A Rutherford

Abstract

Down syndrome is the most common genetic developmental disorder in humans and is caused by partial or complete triplication of human chromosome 21 (trisomy 21). It is a complex condition which results in multiple lifelong health problems, including varying degrees of intellectual disability and delays in speech, memory, and learning. As both length and quality of life are improving for individuals with Down syndrome, attention is now being directed to understanding and potentially treating the associated cognitive difficulties and their underlying biological substrates. These have included imaging and postmortem studies which have identified decreased regional brain volumes and histological anomalies that accompany early onset dementia. In addition, advances in genome-wide analysis and Down syndrome mouse models are providing valuable insight into potential targets for intervention that could improve neurogenesis and long-term cognition. As little is known about early brain development in human Down syndrome, we review recent advances in magnetic resonance imaging that allow non-invasive visualization of brain macro- and microstructure, even in utero. It is hoped that together these advances may enable Down syndrome to become one of the first genetic disorders to be targeted by antenatal treatments designed to 'normalize' brain development. WHAT THIS PAPER ADDS: Magnetic resonance imaging can provide non-invasive characterization of early brain development in Down syndrome. Down syndrome mouse models enable study of underlying pathology and potential intervention strategies. Potential therapies could modify brain structure and improve early cognitive levels. Down syndrome may be the first genetic disorder to have targeted therapies which alter antenatal brain development.

© 2019 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press.

Figures

Figure 1
Figure 1
T2 fetal image reconstruction. Top row: One loop of single shot T2 images acquired in the coronal plane (centre). Numerous black lines in the sagittal and axial images represent missing or motion corrupted data. Bottom row: The reconstructed images have been obtained by registering several loops of single shot T2 images to provide high signal to noise, high resolution volumetric data sets.87, 88, 89, 90
Figure 2
Figure 2
Segmentation of the brain from a fetus with Down syndrome at 33+2 gestational weeks. Semi‐automated segmentation of T2‐weighted volumetric magnetic resonance images showing (a) whole brain; excluding cerebellum (red), (b) cortex (green), (c) lateral ventricles (dark blue), (d) extra cerebral cerebrospinal fluid (light blue), (e) cerebellar hemispheres (purple), cerebellar vermis (bright green), pons (yellow), and fourth ventricle (blue).97 [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 3
Figure 3
Automated segmentation of a brain from a neonate with Down syndrome at 42+5 weeks post menstrual age. T2‐weighted neonatal brain volumetric images in axial, sagittal, and coronal planes (left to right) segmented into multiple brain regions. (a) Raw T2 acquisition, (b) segmentation with nine regions of interest, and (c) segmentation with 87 regions of interest.98, 99, 100 [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 4
Figure 4
Fetal brain development. T2‐weighted axial images from fetal (23+6–38+2 GA) and neonatal (40+0 GA) magnetic resonance imaging showing development of the brain across gestation. Note the marked increase in cortical complexity with increasing gestation. GA, gestational age expressed as weeks+days.
Figure 5
Figure 5
T2‐weighted fetal magnetic resonance imaging in a control fetus and a fetus with Down syndrome. T2‐weighted axial images showing the fourth (a,b) and lateral ventricle (c,d) in control (34+1 GA; a,c) and fetus with Down syndrome (33+2 GA; b,d). White arrows indicate enlarged fourth and lateral ventricles in a fetus with Down syndrome. T2‐weighted sagittal (e,g) and axial (f,h) images in a fetus with Down syndrome (30wks GA, g,h) compared to an age matched control (30wks GA, e,f). Red arrow indicates cerebellar vermis rotation (g) and fourth ventricle enlargement (h). GA, gestational age expressed as weeks+days. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 6
Figure 6
Fetal diffusion tensor imaging. Top row: Fibre orientations distributions per voxel. Bottom row: Tractography demonstrating major connections within the developing brain. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 7
Figure 7
Neuronal staining in the cortex of human fetal postmortem tissue. HuC/HuD, a marker for all neurons in brain from control fetus at 22+2 GA (a) and fetus with Down syndrome at 21+1 GA (c). In the fetal brain with Down syndrome (c,d), the black arrow indicates evidence of aberrant cortical folding, a ‘wavy’ pattern which is in contrast to the control brain (a,b) (Research Ethics Committee UK: 07/H0707/139). Scale bar=500μm. T2‐weighted fetal magnetic resonance imaging in the axial plane show decreased cortical folding in a fetus with Down syndrome (d), compared to an aged matched control (b). GA, gestational age expressed as weeks+days. [Colour figure can be viewed at wileyonlinelibrary.com]

References

    1. Hill M, Barrett A, Choolani M, Lewis C, Fisher J, Chitty LS. Has noninvasive prenatal testing impacted termination of pregnancy and live birth rates of infants with Down syndrome? Prenat Diagn 2017; 37: 1281–90.
    1. Wu J, Morris JK. Trends in maternal age distribution and the live birth prevalence of Down's syndrome in England and Wales: 1938–2010. Eur J Hum Genet 2013; 21: 943–7.
    1. Gupta M, Dhanasekaran AR, Gardiner KJ. Mouse models of Down syndrome: gene content and consequences. Mamm Genome 2016; 27: 538–55.
    1. Lyle R, Béna F, Gagos S, et al. Genotype‐phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum Genet 2009; 17: 454–66.
    1. Korbel JO, Tirosh‐Wagner T, Urban AE, et al. The genetic architecture of Down syndrome phenotypes revealed by high‐resolution analysis of human segmental trisomies. Proc Natl Acad Sci USA 2009; 106: 12031–6.
    1. Guedj F, Pennings JL, Massingham LJ, et al. An integrated human/murine transcriptome and pathway approach to identify prenatal treatments for Down syndrome. Sci Rep 2016; 6: 32353.
    1. El Hajj N, Dittrich M, Böck J, et al. Epigenetic dysregulation in the developing Down syndrome cortex. Epigenetics 2016; 11: 563–78.
    1. Henneman P, Bouman A, Mul A, et al. Widespread domain‐like perturbations of DNA methylation in whole blood of Down syndrome neonates. PLoS ONE 2018; 13: e0194938.
    1. Lott IT. Neurological phenotypes for Down syndrome across the life span. Prog Brain Res 2012; 197: 101–21.
    1. Head E, Lott IT, Wilcock DM, Lemere CA. Aging in Down syndrome and the development of Alzheimer's disease neuropathology. Curr Alzheimer Res 2016; 13: 18–29.
    1. Wiseman FK, Al‐Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci 2015; 16: 564–74.
    1. Karmiloff‐Smith A, Al‐Janabi T, D'Souza H, et al. The importance of understanding individual differences in Down syndrome. F1000Research 2016; 5; 1–10. F1000 Faculty Rev‐389.
    1. Hithersay R, Startin CM, Hamburg S, et al. Association of dementia with mortality among adults with Down syndrome older than 35 years. JAMA Neurol 2019; 76: 152–160. 10.1001/jamaneurol.2018.3616. [Epub ahead of print]
    1. Antonarakis SE, Epstein CJ. The challenge of Down syndrome. Trends Mol Med 2006; 12: 473–9.
    1. Määttä T, Tervo‐Määttä T, Taanila A, Kaski M, Iivanainen M. Mental health, behaviour and intellectual abilities of people with Down syndrome. Downs Syndr Res Pract 2006; 11: 37–43.
    1. de Sola S, de la Torre R, Sánchez‐Benavides G, et al. A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. Front Psychol 2015; 6: 708.
    1. Dierssen M. Down syndrome: the brain in trisomic mode. Nat Rev Neurosci 2012; 13: 844–58.
    1. Gardiner K, Herault Y, Lott IT, Antonarakis SE, Reeves RH, Dierssen M. Down syndrome: from understanding the neurobiology to therapy. J Neurosci 2010; 30: 14943–5.
    1. Contestabile A, Benfenati F, Gasparini L. Communication breaks‐Down: from neurodevelopment defects to cognitive disabilities in Down syndrome. Prog Neurobiol 2010; 91: 1–22.
    1. Chapman RS, Hesketh LJ. Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev 2000; 6: 84–95.
    1. DiGuiseppi C, Hepburn S, Davis JM, et al. Screening for autism spectrum disorders in children with Down syndrome: population prevalence and screening test characteristics. J Dev Behav Pediatr 2010; 31: 181–91.
    1. Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta‐analysis. Lancet Psychiatry 2015; 2: 909–16.
    1. Moss J, Richards C, Nelson L, Oliver C. Prevalence of autism spectrum disorder symptomatology and related behavioural characteristics in individuals with Down syndrome. Autism 2013; 17: 390–404.
    1. Arya R, Kabra M, Gulati S. Epilepsy in children with Down syndrome. Epileptic Disord 2011; 13: 1–7.
    1. Barca D, Tarta‐Arsene O, Dica A, et al. Intellectual disability and epilepsy in down syndrome. Maedica 2014; 9: 344–50.
    1. Freeman SB, Bean LH, Allen EG, et al. Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. Genet Med 2008; 10: 173–80.
    1. Mogra R, Zidere V, Allan LD. Prenatally detectable congenital heart defects in fetuses with Down syndrome. Ultrasound Obstet Gynecol 2011; 38: 320–4.
    1. Alsaied T, Marino BS, Esbensen AJ, Anixt JS, Epstein JN, Cnota JF. Does congenital heart disease affect neurodevelopmental outcomes in children with Down syndrome? Congenit Heart Dis 2016; 11: 26–33.
    1. Visootsak J, Huddleston L, Buterbaugh A, Perkins A, Sherman S, Hunter J. Influence of CHDs on psycho‐social and neurodevelopmental outcomes in children with Down syndrome. Cardiol Young 2016; 26: 250–6.
    1. Pinter JD, Eliez S, Schmitt JE, Capone GT, Reiss AL. Neuroanatomy of Down's syndrome: a high‐resolution MRI study. Am J Psychiatry 2001; 158: 1659–65.
    1. Lee NR, Adeyemi EI, Lin A, et al. Dissociations in cortical morphometry in youth with Down syndrome: evidence for reduced surface area but increased thickness. Cereb Cortex 2016; 26: 2982–90.
    1. Cole JH, Annus T, Wilson LR, et al. Brain‐predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline. Neurobiol Aging 2017; 56: 41–9.
    1. Koran ME, Hohman TJ, Edwards CM, et al. Differences in age‐related effects on brain volume in Down syndrome as compared to Williams syndrome and typical development. J Neurodev Disord 2014; 6: 8.
    1. Guihard‐Costa AM, Khung S, Delbecque K, Ménez F, Delezoide AL. Biometry of face and brain in fetuses with trisomy 21. Pediatr Res 2006; 59: 33–8.
    1. Schmidt‐Sidor B, Wisniewski KE, Shepard TH, Sersen EA. Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. Clin Neuropathol 1990; 9: 181–90.
    1. Larsen KB, Laursen H, Graem N, Samuelsen GB, Bogdanovic N, Pakkenberg B. Reduced cell number in the neocortical part of the human fetal brain in Down syndrome. Ann Anat 2008; 190: 421–7.
    1. Guidi S, Bonasoni P, Ceccarelli C, et al. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol 2008; 18: 180–97.
    1. Guidi S, Ciani E, Bonasoni P, Santini D, Bartesaghi R. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome. Brain Pathol 2011; 21: 361–73.
    1. Guidi S, Giacomini A, Stagni F, et al. Abnormal development of the inferior temporal region in fetuses with Down syndrome. Brain Pathol 2018; 28: 986–98.
    1. Contestabile A, Fila T, Ceccarelli C, et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007; 17: 665–78.
    1. Haydar TF, Reeves RH. Trisomy 21 and early brain development. Trends Neurosci 2012; 35: 81–91.
    1. Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics 2007; 120: e1465–71.
    1. Lu J, Esposito G, Scuderi C, et al. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. PLoS ONE 2011; 6: e22126.
    1. Kanaumi T, Milenkovic I, Adle‐Biassette H, Aronica E, Kovacs GG. Non‐neuronal cell responses differ between normal and Down syndrome developing brains. Int J Dev Neurosci 2013; 31: 796–803.
    1. Golden JA, Hyman BT. Development of the superior temporal neocortex is anomalous in trisomy 21. J Neuropathol Exp Neurol 1994; 53: 513–20.
    1. Engidawork E, Lubec G. Molecular changes in fetal Down syndrome brain. J Neurochem 2003; 84: 895–904.
    1. Wisniewski KE, Laure‐Kamionowska M, Wisniewski HM. Evidence of arrest of neurogenesis and synaptogenesis in brains of patients with Down's syndrome. N Engl J Med 1984; 311: 1187–8.
    1. Takashima S, Becker LE, Armstrong DL, Chan F. Abnormal neuronal development in the visual cortex of the human fetus and infant with down's syndrome. A quantitative and qualitative Golgi study. Brain Res 1981; 225: 1–21.
    1. Wisniewski KE. Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am J Med Genet Suppl 1990; 7: 274–81.
    1. Becker LE, Armstrong DL, Chan F. Dendritic atrophy in children with Down's syndrome. Ann Neurol 1986; 20: 520–6.
    1. Wisniewski KE, Schmidt‐Sidor B. Postnatal delay of myelin formation in brains from Down syndrome infants and children. Clin Neuropathol 1989; 8: 55–62.
    1. Lu J, Lian G, Zhou H, et al. OLIG2 over‐expression impairs proliferation of human Down syndrome neural progenitors. Hum Mol Genet 2012; 21: 2330–40.
    1. Guedj F, Pereira PL, Najas S, et al. DYRK1A: a master regulatory protein controlling brain growth. Neurobiol Dis 2012; 46: 190–203.
    1. Lott IT. Antioxidants in Down syndrome. Biochim Biophys Acta 2012; 1822: 657–63.
    1. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet 2004; 5: 725–38.
    1. Stagni F, Giacomini A, Guidi S, Ciani E, Bartesaghi R. Timing of therapies for Down syndrome: the sooner, the better. Front Behav Neuroscie 2015; 9: 265.
    1. Herault Y, Delabar JM, Fisher EMC, Tybulewicz VLJ, Yu E, Brault V. Rodent models in Down syndrome research: impact and future opportunities. Dis Model Mech 2017; 10: 1165–86.
    1. Contestabile A, Magara S, Cancedda L. The GABAergic hypothesis for cognitive disabilities in Down syndrome. Front Cell Neurosci 2017; 11: 54.
    1. Stagni F, Giacomini A, Emili M, Guidi S, Bartesaghi R. Neurogenesis impairment: an early developmental defect in Down syndrome. Free Radic Biology Med 2018; 114: 15–32.
    1. Duchon A, Raveau M, Chevalier C, Nalesso V, Sharp AJ, Herault Y. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm Genome 2011; 22: 674–84.
    1. Reinholdt LG, Ding Y, Gilbert GJ, et al. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm Genome 2011; 22: 685–91.
    1. Sago H, Carlson EJ, Smith DJ, et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc Natl Acad Sci USA 1998; 95: 6256–61.
    1. Rahmani Z, Blouin JL, Créau‐Goldberg N, et al. Down syndrome critical region around D21S55 on proximal 21q22.3. Am J Med Genet Suppl 1990; 7: 98–103.
    1. McCormick MK, Schinzel A, Petersen MB, et al. Molecular genetic approach to the characterization of the ‘Down syndrome region’ of chromosome 21. Genomics 1989; 5: 325–31.
    1. Olson LE, Richtsmeier JT, Leszl J, Reeves RH. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 2004; 306: 687–90.
    1. Korenberg JR, Chen XN, Schipper R, et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci USA 1994; 91: 4997–5001.
    1. O'Doherty A, Ruf S, Mulligan C, et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005; 309: 2033–7.
    1. Wiseman FK, Pulford LJ, Barkus C, et al. Trisomy of human chromosome 21 enhances amyloid‐beta deposition independently of an extra copy of APP. Brain 2018; 141: 2457–74.
    1. Yu T, Li Z, Jia Z, et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet 2010; 19: 2780–91.
    1. Lana‐Elola E, Watson‐Scales S, Slender A, et al. Genetic dissection of Down syndrome‐associated congenital heart defects using a new mouse mapping panel. Elife 2016; 5; e11614: pii: e11614.
    1. Semple BD, Blomgren K, Gimlin K, Ferriero DM, Noble‐Haeusslein LJ. Brain development in rodents and humans: identifying benchmarks of maturation and vulnerability to injury across species. Progress Neurobiol 2013; 106–107: 1–16.
    1. Guedj F, Pennings JL, Ferres MA, et al. The fetal brain transcriptome and neonatal behavioral phenotype in the Ts1Cje mouse model of Down syndrome. Am J Med Genet A 2015; 167A: 1993–2008.
    1. Goodliffe JW, Olmos‐Serrano JL, Aziz NM, et al. Absence of prenatal forebrain defects in the Dp(16)1Yey/+ mouse model of Down syndrome. J Neurosci 2016; 36: 2926–44.
    1. Aziz NM, Guedj F, Pennings JLA, et al. Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome. Dis Model Mech 2018; 11: dmm031013.
    1. Eady N, Sheehan R, Rantell K, et al. Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study. Br J Psychiatry 2018; 212: 155–60.
    1. Rafii MS, Skotko BG, McDonough ME, et al. A randomized, double‐blind, placebo‐controlled, phase II study of oral ELND005 (scyllo‐Inositol) in young adults with Down syndrome without dementia. J Alzheimers Dis 2017; 58: 401–11.
    1. Kelly CJ, Makropoulos A, Cordero‐Grande L, et al. Impaired development of the cerebral cortex in infants with congenital heart disease is correlated to reduced cerebral oxygen delivery. Sci Rep 2017; 7: 15088.
    1. Kelly CJ, Christiaens D, Batalle D, et al. Abnormal microstructural development of the cerebral cortex in neonates with congenital heart disease is associated with impaired cerebral oxygen delivery. J Am Heart Assoc 2019; 8: e009893.
    1. Moore CS. Postnatal lethality and cardiac anomalies in the Ts65Dn Down syndrome mouse model. Mamm Genome 2006; 17: 1005–12.
    1. Ferrés MA, Bianchi DW, Siegel AE, Bronson RT, Huggins GS, Guedj F. Perinatal natural history of the Ts1Cje mouse model of Down syndrome: growth restriction, early mortality, heart defects, and delayed development. PLoS ONE 2016; 11: e0168009.
    1. Dunlevy L, Bennett M, Slender A, et al. Down's syndrome‐like cardiac developmental defects in embryos of the transchromosomic Tc1 mouse. Cardiovasc Res 2010; 88: 287–95.
    1. Olmos‐Serrano JL, Kang HJ, Tyler WA, et al. Down syndrome developmental brain transcriptome reveals defective oligodendrocyte differentiation and myelination. Neuron 2016; 89: 1208–22.
    1. Griffiths PD, Bradburn M, Campbell MJ, et al. Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort study. Lancet 2017; 389: 538–46.
    1. Kelly CJ, Hughes EJ, Rutherford MA, Counsell SJ. Advances in neonatal MRI of the brain: from research to practice. Arch Dis Child Educ Pract Ed 2019; 104: 106–10.
    1. Hamner T, Udhnani MD, Osipowicz KZ, Lee NR. Pediatric brain development in Down syndrome: a field in its infancy. J Int Neuropsychol Soc 2018; 24: 966–76.
    1. Neale N, Padilla C, Fonseca LM, Holland T, Zaman S. Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome. Neuroimage Clin 2018; 17: 263–71.
    1. Malamateniou C, Malik SJ, Counsell SJ, et al. Motion‐compensation techniques in neonatal and fetal MR imaging. AJNR Am J Neuroradiol 2013; 34: 1124–36.
    1. Jiang S, Xue H, Glover A, Rutherford M, Rueckert D, Hajnal JV. MRI of moving subjects using multislice snapshot images with volume reconstruction (SVR): application to fetal, neonatal, and adult brain studies. IEEE Trans Med Imaging 2007; 26: 967–80.
    1. Jiang S, Xue H, Counsell S, et al. Diffusion tensor imaging (DTI) of the brain in moving subjects: application to in‐utero fetal and ex‐utero studies. Magn Reson Med 2009; 62: 645–55.
    1. Ferrazzi G, Kuklisova Murgasova M, Arichi T, et al. Resting State fMRI in the moving fetus: a robust framework for motion, bias field and spin history correction. NeuroImage 2014; 101: 555–68.
    1. Kuklisova‐Murgasova M, Quaghebeur G, Rutherford MA, Hajnal JV, Schnabel JA. Reconstruction of fetal brain MRI with intensity matching and complete outlier removal. Med Image Anal 2012; 16: 1550–64.
    1. Hughes EJ, Winchman T, Padormo F, et al. A dedicated neonatal brain imaging system. Magn Reson Medicine 2017; 78: 794–804.
    1. Raschle N, Zuk J, Ortiz‐Mantilla S, et al. Pediatric neuroimaging in early childhood and infancy: challenges and practical guidelines. Ann N Y Acad Sci 2012; 1252: 43–50.
    1. Thieba C, Frayne A, Walton M, et al. Factors associated with successful MRI scanning in unsedated young children. Front Pediatr 2018; 6: 146.
    1. Loepke AW. Developmental neurotoxicity of sedatives and anesthetics: a concern for neonatal and pediatric critical care medicine? Pediatr Crit Care Med 2010; 11: 217–26.
    1. Dean DC 3rd, Dirks H, O'Muircheartaigh J, et al. Pediatric neuroimaging using magnetic resonance imaging during non‐sedated sleep. Pediatr Radiol 2014; 44: 64–72.
    1. Wright R, Makropoulos A, Kyriakopoulou V, et al. Construction of a fetal spatio‐temporal cortical surface atlas from in utero MRI: application of spectral surface matching. NeuroImage 2015; 120: 467–80.
    1. Makropoulos A, Aljabar P, Wright R, et al. Regional growth and atlasing of the developing human brain. NeuroImage 2016; 125: 456–78.
    1. Makropoulos A, Gousias IS, Ledig C, et al. Automatic whole brain MRI segmentation of the developing neonatal brain. IEEE Trans Med Imaging 2014; 33: 1818–31.
    1. Gousias IS, Hammers A, Counsell SJ, et al. Magnetic resonance imaging of the newborn brain: automatic segmentation of brain images into 50 anatomical regions. PLoS ONE 2013; 8: e59990.
    1. Kyriakopoulou V, Vatansever D, Davidson A, et al. Normative biometry of the fetal brain using magnetic resonance imaging. Brain Struct Funct 2017; 222: 2295–307.
    1. Counsell SJ, Edwards AD, Chew AT, et al. Specific relations between neurodevelopmentalin abilities and white matter microstructure in children born preterm. Brain 2008; 131: 3201–8.
    1. Massaro AN, Evangelou I, Fatemi A, et al. White matter tract integrity and developmental outcome in newborn infants with hypoxic‐ischemic encephalopathy treated with hypothermia. Dev Med Child Neurol 2015; 57: 441–8.
    1. Ball G, Boardman JP, Arichi T, et al. Testing the sensitivity of Tract‐Based Spatial Statistics to simulated treatment effects in preterm neonates. PLoS ONE 2013; 8: e67706.
    1. Raffelt DA, Tournier JD, Smith RE, et al. Investigating white matter fibre density and morphology using fixel‐based analysis. NeuroImage 2017; 144: 58–73.
    1. Powell D, Caban‐Holt A, Jicha G, et al. Frontal white matter integrity in adults with Down syndrome with and without dementia. Neurobiol Aging 2014; 35: 1562–9.
    1. Gunbey HP, Bilgici MC, Aslan K, et al. Structural brain alterations of Down's syndrome in early childhood evaluation by DTI and volumetric analyses. Eur Radiol 2017; 27: 3013–21.
    1. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990; 87: 9868–72.
    1. Allievi AG, Arichi T, Tusor N, et al. Maturation of sensori‐motor functional responses in the preterm brain. Cereb Cortex 2016; 26: 402–13.
    1. Thomason ME, Grove LE, Lozon TA Jr, et al. Age‐related increases in long‐range connectivity in fetal functional neural connectivity networks in utero. Dev Cogn Neurosci 2015; 11: 96–104.
    1. Doria V, Beckmann CF, Arichi T, et al. Emergence of resting state networks in the preterm human brain. Proc Natl Acad Sci USA 2010; 107: 20015–20.
    1. Fransson P, Skiöld B, Horsch S, et al. Resting‐state networks in the infant brain. Proc Natl Acad Sci USA 2007; 104: 15531–6.
    1. Smyser CD, Neil JJ. Use of resting‐state functional MRI to study brain development and injury in neonates. Semin Perinatol 2015; 39: 130–40.
    1. Anderson JS, Nielsen JA, Ferguson MA, et al. Abnormal brain synchrony in Down Syndrome. Neuroimage Clin 2013; 2: 703–15.
    1. de la Torre R, de Sola S, Hernandez G, et al. Safety and efficacy of cognitive training plus epigallocatechin‐3‐gallate in young adults with Down's syndrome (TESDAD): a double‐blind, randomised, placebo‐controlled, phase 2 trial. Lancet Neurol 2016; 15: 801–10.
    1. Park HJ, Friston K. Structural and functional brain networks: from connections to cognition. Science 2013; 342: 1238411.
    1. Story L, Damodaram MS, Allsop JM, et al. Proton magnetic resonance spectroscopy in the fetus. Eur J Obstet Gynecol Reprod Biol 2011; 158: 3–8.
    1. Berry GT, Wang ZJ, Dreha SF, Finucane BM, Zimmerman RA. In vivo brain myo‐inositol levels in children with Down syndrome. J Pediatr 1999; 135: 94–7.
    1. Beacher F, Simmons A, Daly E, et al. Hippocampal myo‐inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2005; 62: 1360–5.
    1. Shonk T, Ross BD. Role of increased cerebral myo‐inositol in the dementia of Down syndrome. Magn Reson Med 1995; 33: 858–61.
    1. Huang W, Alexander GE, Daly EM, et al. High brain myo‐inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. Am J Psychiatry 1999; 156: 1879–86.
    1. Lin AL, Powell D, Caban‐Holt A, et al. (1)H‐MRS metabolites in adults with Down syndrome: effects of dementia. Neuroimage Clin 2016; 11: 728–35.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe